TP53 dysfunction in chronic lymphocytic leukemia: clinical relevance in the era of B-cell receptors and BCL-2 inhibitors.

Antineoplastic Agents / pharmacology High-Throughput Nucleotide Sequencing Humans Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy Mutation Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors Tumor Suppressor Protein p53 / genetics
TP53 mutations BCL2 inhibitor BCR inhibitors chronic Lymphocytic Leukemia clinical outcome del(17p) ibrutinib idelalisib venetoclax

Journal

Expert opinion on investigational drugs
ISSN: 1744-7658
Titre abrégé: Expert Opin Investig Drugs
Pays: England
ID NLM: 9434197

Informations de publication

Date de publication:
Aug 2020
Historique:
pubmed: 20 6 2020
medline: 3 2 2021
entrez: 20 6 2020
Statut: ppublish

Résumé

Patients with A literature search was undertaken on clinical trials and real-world experience data on patients with Although

Identifiants

DOI: 10.1080/13543784.2020.1783239 PMID: 32551999
pubmed: 32551999
doi: 10.1080/13543784.2020.1783239
doi:

Substances chimiques

Antineoplastic Agents 0
BCL2 protein, human 0
Proto-Oncogene Proteins c-bcl-2 0
TP53 protein, human 0
Tumor Suppressor Protein p53 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

869-880

Auteurs

Fortunato Morabito (F)

Hematology Department and Bone Marrow Transplant Unit, Cancer Care Center, Augusta Victoria Hospital , Jerusalem, Israel.
Biotechnology Research Unit, Aprigliano, AO/ASP , Cosenza, Italy.

Massimo Gentile (M)

Biotechnology Research Unit, Aprigliano, AO/ASP , Cosenza, Italy.
Hematology Unit, Hematology and Oncology Department , Cosenza, Italy.

Paola Monti (P)

Mutagenesis and Cancer Prevention Unit, IRCCS Ospedale Policlinico San Martino , Genoa, Italy.
ORCID: 0000-0002-1978-4998

Anna Grazia Recchia (AG)

Biotechnology Research Unit, Aprigliano, AO/ASP , Cosenza, Italy.

Paola Menichini (P)

Mutagenesis and Cancer Prevention Unit, IRCCS Ospedale Policlinico San Martino , Genoa, Italy.

Mamdouh Skafi (M)

Hematology Department and Bone Marrow Transplant Unit, Cancer Care Center, Augusta Victoria Hospital , Jerusalem, Israel.

Moien Atrash (M)

Hematology Department and Bone Marrow Transplant Unit, Cancer Care Center, Augusta Victoria Hospital , Jerusalem, Israel.

Giuseppa De Luca (G)

Molecular Diagnostic Unit, IRCCS Ospedale Policlinico San Martino , Genoa, Italy.

Sabrina Bossio (S)

Biotechnology Research Unit, Aprigliano, AO/ASP , Cosenza, Italy.

Hamdi Al-Janazreh (H)

Hematology Department and Bone Marrow Transplant Unit, Cancer Care Center, Augusta Victoria Hospital , Jerusalem, Israel.

Sara Galimberti (S)

Section of Hematology, University of Pisa , Pisa, Italy.

Zaidoun Salah (Z)

The Lautenberg Center for General and Tumor Immunology, Department of Immunology and Cancer Research-Institute for Medical Research Israel-Canada, Hebrew University-Hadassah Medical School , Jerusalem, Israel.

Lucio Morabito (L)

Humanitas Clinical and Research Center, IRCCS , Rozzano, Italy.

Alham Mujahed (A)

Laboratory Department, Cancer Care Center, Augusta Victoria Hospital , Jerusalem, Israel.

Musa Hindiyeh (M)

Laboratory Department, Cancer Care Center, Augusta Victoria Hospital , Jerusalem, Israel.

Mariella Dono (M)

Molecular Diagnostic Unit, IRCCS Ospedale Policlinico San Martino , Genoa, Italy.

Franco Fais (F)

Molecular Pathology Unit, IRCCS Ospedale Policlinico San Martino , Genova, Italy.
Department of Experimental Medicine, University of Genoa , Genoa, Italy.

Giovanna Cutrona (G)

Molecular Pathology Unit, IRCCS Ospedale Policlinico San Martino , Genova, Italy.

Antonino Neri (A)

Department of Oncology and Hemato-Oncology, University of Milan , Milan, Italy.
Hematology Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico , Milan, Italy.

Giovanni Tripepi (G)

Research Unit of Reggio Calabria , Reggio Calabria, Italy.

Gilberto Fronza (G)

Mutagenesis and Cancer Prevention Unit, IRCCS Ospedale Policlinico San Martino , Genoa, Italy.

Manlio Ferrarini (M)

Department of Experimental Medicine, University of Genoa , Genoa, Italy.

Articles similaires

Comprehensive comparative analysis and development of molecular markers for Lasianthus species based on complete chloroplast genome sequences.

Yue Zhang, Meifang Song, Deying Tang et al.
1.00
Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › TP53 dysfunction in chronic lymphocytic...
questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Analyse de séquence › Séquençage nucléotidique à haut débit › TP53 dysfunction in chronic lymphocytic...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › TP53 dysfunction in chronic lymphocytic...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladie chronique › Leucémie chronique lymphocytaire à cellules B › TP53 dysfunction in chronic lymphocytic...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › TP53 dysfunction in chronic lymphocytic...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Protéines oncogènes › Protéines proto-oncogènes › Protéines proto-oncogènes c-bcl-2 › TP53 dysfunction in chronic lymphocytic...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Phosphoprotéines › Protéine p53 suppresseur de tumeur › TP53 dysfunction in chronic lymphocytic...